# Reproxalap PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/reproxalap

> Reproxalap, sponsored by Aldeyra Therapeutics, Inc. (ALDX), received a complete response letter from the FDA; the decision is dated September 29, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is reproxalap FDA approved?

Not as of November 16, 2026. Reproxalap, sponsored by Aldeyra Therapeutics, Inc. (ALDX), received a complete response letter from the FDA; the decision is dated September 29, 2026. SEC Form 8-K: "Based on the Type D meeting, on September 29, 2026, Aldeyra issued a press release (the Press Release) announcing the intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND), appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." [Calendar and source filings](https://sec-api.dev/pdufa/reproxalap)

Source: SEC Form 8-K, accession 0001193125-26-405954, https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm (retrieved 2026-11-12). Last confirmed 2026-09-29. Cite: https://sec-api.dev/pdufa/reproxalap#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | reproxalap |
| Codes |  |
| Sponsor | Aldeyra Therapeutics, Inc. (ALDX) https://sec-api.dev/companies/aldx/catalysts |
| Indications | [signs and symptoms of dry eye disease in december 2022](https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022), [dry eye disease](https://sec-api.dev/indications/dry-eye-disease), [signs and symptoms of dry eye disease](https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease), signs and symptoms of dry eye disease in october 2024, immune-mediated diseases, today, dry eye disease and |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2022: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-04-03, last confirmed 2025-04-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-072424): "Among other clinical trials of reproxalap, Aldeyra previously conducted two trials for ocular redness (a dry eye disease sign) in a dry eye chamber, and two dry eye disease symptom field (environmental exposure) trials, which were submitted as part of an initial NDA in November 2022." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex992.htm

### November 23, 2023: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-02-28, last confirmed 2025-05-14.
- SEC Form 10-Q (accession 0000950170-25-071602): "In February 2023, the FDA accepted the Reproxalap NDA for filing and set a PDUFA date of November 23, 2023." https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-030102): "In February 2023, the FDA accepted the reproxalap NDA for filing and set a PDUFA date of November 23, 2023." https://www.sec.gov/Archives/edgar/data/1341235/000095017025030102/aldx-20241231.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm

### November 27, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: signs and symptoms of dry eye disease in December 2022.
- First seen 2025-02-28, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-449742): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "On November 27, 2023, we announced that we had received a Complete Response Letter from the FDA (the reproxalap Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "On November 27, 2023, we announced that we had received a Complete Response Letter from the FDA (the reproxalap Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071602): "On November 27, 2023, we announced that we had received a Complete Response Letter from the FDA (the reproxalap Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-030102): "On November 27, 2023, we announced that we had received a Complete Response Letter from the FDA (the reproxalap Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025030102/aldx-20241231.htm

### November 27, 2023: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: signs and symptoms of dry eye disease in December 2022.
- First seen 2026-02-27, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-449742): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm

### Oct 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: signs and symptoms of dry eye disease in October 2024.
- First seen 2025-04-03, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001193125-26-109511): "Aldeyra resubmitted an NDA (the "reproxalap NDA") for reproxalap for the treatment of the signs and symptoms of dry eye disease in October 2024." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 8-K (accession 0001193125-25-072424): "Aldeyra resubmitted an NDA for reproxalap for the treatment of the signs and symptoms of dry eye disease in October 2024." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Response Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Responses Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Responses Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Responses Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "In October 2024, we submitted the Reproxalap NDA, which included results from the completed chamber crossover trial." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "In October 2024, we submitted the Reproxalap NDA, which included results from the completed chamber crossover trial." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm

### Oct 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2026-02-27, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-449742): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Response Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Responses Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Responses Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Responses Letters) with respect to the resubmission." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm

### November 15, 2024: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: signs and symptoms of dry eye disease.
- First seen 2024-11-18, last confirmed 2026-03-17.
- SEC Form 8-K (accession 0001213900-24-099333): "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm
- SEC Form 8-K (accession 0001193125-26-109511): "In November 2024, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 8-K (accession 0001193125-25-072424): "In November 2024, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "On November 18, 2024, we announced that the FDA had accepted for review the Reproxalap NDA and assigned a PDUFA date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "On November 18, 2024, we announced that the FDA had accepted for review the Reproxalap NDA and assigned a PDUFA date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- SEC Form 10-K (accession 0000950170-25-030102): "On November 18, 2024, we announced that the FDA accepted for review a resubmitted NDA for reproxalap for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000095017025030102/aldx-20241231.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-04-03, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-072424): "Top-line results from dry eye disease field and chamber clinical trials are expected in Q2 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-072424): "In the second quarter of 2025, Aldeyra expects to announce top-line results from the ongoing dry eye disease field trial and the ongoing chamber clinical trial." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-113275): "Mid-2025 Allergic Conjunctivitis (Reproxalap) Positive Phase 3 INVIGORATE 2 trial top-line results announced Atopic Dermatitis (ADX-248) Phase 1 clinical trial initiated‡ Moderate Alcohol-Associated Hepatitis (ADX-629) Open-label Phase 2 clinical trial top-line results expected in 2025‡ Retinitis Pigmentosa (ADX-2191) Phase 2/3 clinical trial initiation expected in 2025‡ Clinical and Regulatory Milestones ‡The timing of clinical trials depends, in part, on the availability of clinical research facilities and staffing, the ability to recruit patients, and the number of patients in the trial. *Investigator sponsored." https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544dex991.htm

### mid-2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-05-06, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-113275): "Pending the Type A meeting with the FDA, NDA resubmission is anticipated in mid-2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544dex991.htm

### April 2, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: signs and symptoms of dry eye disease.
- First seen 2024-11-18, last confirmed 2026-03-17.
- SEC Form 8-K (accession 0001213900-24-099333): "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm
- SEC Form 8-K (accession 0001213900-24-099333): ""forward-looking statements" under the securities laws, including, but not limited to, statements regarding relating to the likelihood and timing of the FDA's potential approval of the resubmitted NDA for reproxalap by the PDUFA date of April 2, 2025, or at any other time, the adequacy of the data included in the previously submitted NDA and the resubmitted NDA, the potential profile, benefit and market size of reproxalap in dry eye disease should the resubmitted NDA for reproxalap be approved by the FDA." https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm
- SEC Form 8-K (accession 0001193125-26-109511): "In November 2024, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "On November 18, 2024, we announced that the FDA had accepted for review the Reproxalap NDA and assigned a PDUFA date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "On November 18, 2024, we announced that the FDA had accepted for review the Reproxalap NDA and assigned a PDUFA date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- SEC Form 8-K (accession 0001193125-25-072424): "In November 2024, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm
- SEC Form 10-K (accession 0000950170-25-030102): "The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000095017025030102/aldx-20241231.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20250402.pdf%22

### April 2, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: dry eye disease.
- First seen 2025-04-03, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20250402.pdf%22
- SEC Form 8-K (accession 0001193125-25-072424): "On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter ("2025 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's resubmitted New Drug Application ("resubmitted NDA") for reproxalap, an investigational drug candidate, for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "On April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the reproxalap Complete Response Letter, the Complete Responses Letters)." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "On April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the reproxalap Complete Response Letter, the Complete Responses Letters)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071602): "On April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the reproxalap Complete Response Letter, the Complete Responses Letters)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm
- SEC Form 8-K (accession 0001193125-26-109511): "On April 3, 2025, Aldeyra announced that it had received a Complete Response Letter from the FDA (the "2025 Complete Response Letter")." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 8-K (accession 0001193125-25-072424): "On April 3, 2025, Aldeyra announced that it had received the 2025 Complete Response Letter from the FDA." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-072424): "Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex992.htm

### April 3, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: dry eye disease.
- First seen 2025-04-03, last confirmed 2025-04-03.
- SEC Form 8-K (accession 0001193125-25-072424): "On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter ("2025 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's resubmitted New Drug Application ("resubmitted NDA") for reproxalap, an investigational drug candidate, for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm

### Jun 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-08-07, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001193125-26-109511): "In June 2025, Aldeyra resubmitted the reproxalap NDA, which, based on written agreement with the FDA, primarily consisted of results from the additional dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "In June 2025, we resubmitted the Reproxalap NDA, which, based on written agreement with the FDA, primarily consisted of results from the additional dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "In June 2025, we resubmitted the Reproxalap NDA, which, based on written agreement with the FDA, primarily consisted of results from the additional dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "In June 2025, we resubmitted the Reproxalap NDA, which, based on written agreement with the FDA, primarily consisted of results from the additional dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "In June 2025, we resubmitted the Reproxalap NDA, which, based on written agreement with the FDA, primarily consisted of results from the additional dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "In June 2025, we submitted the Reproxalap NDA, which included results from the completed dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "In June 2025, we submitted the Reproxalap NDA, which included results from the completed dry eye chamber trial." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm

### July 17, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: signs and symptoms of dry eye disease.
- First seen 2025-07-17, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001193125-26-109511): "On July 17, 2025, Aldeyra announced that the FDA accepted the reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-064869): "Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea024925701ex99-1_aldeyra.htm

### December 15, 2025: PDUFA date

- Status: delayed. Date confidence: exact. Indication: signs and symptoms of dry eye disease.
- First seen 2025-12-16, last confirmed 2025-12-16.
- SEC Form 8-K (accession 0001193125-25-319638): "On December 15, 2025, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") issued a press release (the "Press Release") to announce that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ("PDUFA") date for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-20251215.htm
- SEC Form 8-K (accession 0001193125-25-319638): "As reported in Item 7.01 of this Current Report on Form 8-K, on December 15, 2025, the Company issued the Press Release to announce the PDUFA extension for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-20251215.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-319638): "December 15, 2025 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm

### December 16, 2025: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: signs and symptoms of dry eye disease.
- First seen 2025-07-17, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001193125-26-109511): "On July 17, 2025, Aldeyra announced that the FDA accepted the reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "On July 17, 2025, we announced that the FDA accepted the Reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- SEC Form 8-K (accession 0001213900-25-064869): "Administration ("FDA") has accepted for review Aldeyra's resubmitted New Drug Application ("NDA") for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea0249257-8k_aldeyra.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-319638): "Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-319638): "Aldeyra will host a conference call at 8:00 a.m. ET tomorrow, Tuesday December 16, 2025, to discuss the PDUFA extension." https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-064869): "The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025." https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea024925701ex99-1_aldeyra.htm

### March 16, 2026: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-02-27, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001193125-26-109511): "On December 15, 2025, Aldeyra announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "On December 15, 2025, we announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "On December 15, 2025, we announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "On December 15, 2025, we announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "On December 15, 2025, we announced that the FDA had requested submission of the field trial, triggering an extension of the PDUFA date to March 16, 2026." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20260316.pdf%22

### March 16, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: dry eye disease.
- First seen 2026-03-17, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20260316.pdf%22
- SEC Form 8-K (accession 0001193125-26-109511): "On March 17, 2026, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") issued a press release (the "Press Release") to announce receipt of a Complete Response Letter ("2026 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's New Drug Application for reproxalap ("reproxalap NDA"), an investigational drug candidate, for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "On March 17, 2026, following re-submission of the Reproxalap NDA, we announced receipt of the 2026 Complete Response Letter from the FDA." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 8-K (accession 0001193125-26-109511): "On March 17, 2026, Aldeyra announced that it had received a Complete Response Letter from the FDA (the "2026 Complete Response Letter")." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- SEC Form 8-K (accession 0001193125-26-109511): "As reported under Item 7.01 of this Current Report on Form 8-K, on March 17, 2026, Aldeyra announced receipt of the 2026 Complete Response Letter." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-109511): "Lexington, Mass., March 17, 2026 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease." https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "On March 17, 2026, we announced that we had received a Complete Response Letter from the FDA (the 2026 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "On March 17, 2026, we announced that we had received a Complete Response Letter from the FDA (the 2026 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "On March 17, 2026, we announced that we had received a Complete Response Letter from the FDA (the 2026 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm

### May 1, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: dry eye disease and.
- First seen 2026-05-01, last confirmed 2026-05-01.
- SEC Form 8-K (accession 0001193125-26-199157): "On May 1, 2026, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") released an updated corporate overview presentation (the "Corporate Overview") which, among other things, disclosed (i) standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy clinical trials of reproxalap submitted to the New Drug Application for the treatment of dry eye disease and (ii) Aldeyra's abbreviated interpretations of the U.S. Food & Drug Administration positions on the primary endpoints for the reproxalap clinical trials, as well as the Aldeyra positions on the primary endpoints." https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-20260501.htm

### September 29, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: dry eye disease.
- First seen 2026-09-29, last confirmed 2026-09-29.
- SEC Form 8-K (accession 0001193125-26-405954): "Based on the Type D meeting, on September 29, 2026, Aldeyra issued a press release (the Press Release) announcing the intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND), appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm
- SEC Form 8-K (accession 0001193125-26-405954): "As reported under Item 7.01 of this Current Report on Form 8-K, on September 29, 2026, Aldeyra issued the Press Release to announce the intent to submit an FDRR, appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm

## Same indication

- [CLYM116](https://sec-api.dev/pdufa/clym116) (CLYM)

Calendar months: [December 2025](https://sec-api.dev/fda-calendar/2025-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/reproxalap.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Reproxalap PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/reproxalap

```bibtex
@misc{secapidev_pdufa_reproxalap_20261116,
  title        = {Reproxalap PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/reproxalap}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_reproxalap_20261116","title":"Reproxalap PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/reproxalap","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
